Ubs Asset Management Americas Inc Neurocrine Biosciences Inc Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 912,064 shares of NBIX stock, worth $116 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

912,064

Previous 599,424 52.16%

Holding current value

$116 Million

Previous $82.7 Million 51.88%

% of portfolio

0.04%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $40.9 Million - $44.8 Million	312,640 Added 52.16%	912,064 $126 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $2.35 Million - $2.59 Million	-18,029 Reduced 2.92%	599,424 $82.7 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $2.99 Million - $3.74 Million	28,162 Added 4.78%	617,453 $81.4 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $1.92 Million - $2.39 Million	20,413 Added 3.59%	589,291 $66.3 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $2.47 Million - $3.23 Million	26,266 Added 4.84%	568,878 $57.6 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $3.05 Million - $3.63 Million	28,586 Added 5.56%	542,612 $64.8 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $1.45 Million - $1.7 Million	15,788 Added 3.17%	514,026 $54.6 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $1.31 Million - $1.73 Million	-17,330 Reduced 3.36%	498,238 $48.6 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $12 Million - $15.7 Million	165,198 Added 47.15%	515,568 $48.3 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $6.06 Million - $8.08 Million	76,040 Added 27.72%	350,370 $29.8 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $1.51 Million - $1.74 Million	17,566 Added 6.84%	274,330 $26.3 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $15.1 Million - $17.2 Million	-168,462 Reduced 39.62%	256,764 $25 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $21.5 Million - $29.3 Million	-245,739 Reduced 36.62%	425,226 $41.4 Million
Q4 2020 Mar 01, 2021	BUY	$86.91 - $108.33 $8.93 Million - $11.1 Million	102,801 Added 18.09%	670,965 $64.3 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $2.64 Million - $3.7 Million	27,403 Added 5.07%	568,164 $54.6 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $5.27 Million - $8.07 Million	61,881 Added 12.92%	540,761 $66 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $2.51 Million - $3.8 Million	-33,409 Reduced 6.52%	478,880 $41.4 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $9.01 Million - $12.3 Million	103,841 Added 25.42%	512,289 $55.1 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $2.59 Million - $3.14 Million	-30,902 Reduced 7.03%	408,448 $36.8 Million
Q2 2019 Aug 15, 2019	BUY	$72.24 - $91.27 $2.07 Million - $2.61 Million	28,628 Added 6.97%	439,350 $0
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.1 Million - $2.78 Million	30,346 Added 7.98%	410,722 $0
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $14.8 Million - $26.9 Million	216,131 Added 131.59%	380,376 $27.2 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $19.7 Million - $25 Million	-198,975 Reduced 54.78%	164,245 $0
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $1.26 Million - $1.77 Million	-16,719 Reduced 4.4%	363,220 $0
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $6.47 Million - $7.88 Million	-85,253 Reduced 18.33%	379,939 $0
Q4 2017 Feb 09, 2018	SELL	$58.53 - $77.59 $3.19 Million - $4.23 Million	-54,520 Reduced 10.49%	465,192 $0
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $24.9 Million - $31.8 Million	519,712	519,712 $0

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.7M

Call Options Held

642K

Put Options Held

288K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Neurocrine Biosciences Inc Transaction History